Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology

The introduction of biologic DMARDs into rheumatology has resulted in a substantial reduction of the burden of many rheumatic diseases. In the slipstream of the success achieved with these biologic DMARDs, some conventional immunosuppressive drugs have also found use in new indications. Notably, myc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Rheumatology 2020-03, Vol.16 (3), p.167-178
Hauptverfasser:	Broen, Jasper C. A., van Laar, Jacob M.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4023/1670 692/700/565/1436 692/700/565/2194 692/700/565/251/1574 Antirheumatic Agents - pharmacokinetics Antirheumatic Agents - therapeutic use Azathioprine Azathioprine - pharmacokinetics Azathioprine - therapeutic use Calcineurin Cell activation Cell proliferation Clinical trials Drug Therapy, Combination Drugs Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - therapeutic use Fibrosis Historical account Humans Immunosuppressive agents Immunosuppressive Agents - pharmacokinetics Immunosuppressive Agents - therapeutic use Lung diseases Lupus nephritis Lymphocytes Medical treatment Medicine Medicine & Public Health Mycophenolate mofetil Mycophenolic acid Mycophenolic Acid - pharmacokinetics Mycophenolic Acid - therapeutic use Nephritis Patient outcomes Pharmacodynamics Pharmacology, Experimental Review Article Rheumatic diseases Rheumatic Diseases - drug therapy Rheumatology Skin diseases Systemic sclerosis Tacrolimus Tacrolimus - pharmacokinetics Tacrolimus - therapeutic use Transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!